Evidence in favour
- Participation spans 6 named insiders rather than one filing source.
Company insider dossier
Neuroone Medical Technologies Corp insider intelligence
NMTC filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
68/100
Conviction accumulation
53/100 confidence- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical Devices
- Latest evidence
- 28 Aug 2026
Investment committee read
Conviction accumulation
Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.
Research constructive setupsDecision risks
- Reported purpose is unavailable in this feed, so even priced common-share transactions need filing context.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 1.56 USD
- One-week move
- -3.7%
- Four-week move
- -19.6%
- Fair-value gap
- -69.8%
- Trend signal
- Inactive
- Relative strength
- -65.4
Directional balance
Controlled event mix
50.0%acquisition
- Acquisition events
- 1
- Disposal events
- 1
- Net value
- $35.2K
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
129 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
010 Aug
017 Aug
724 Aug
031 Aug
007 Sep
014 Sep
Named participants
Insider conviction by person
WAMBEKE, DAVID J.Chief Business Officer721 events
JOHNS, EMILY J.Chief Administrative Officer500 events
MERTENS, STEVEChief Technology Officer500 events
ROSA, DAVID ADirector, CEO & President500 events
VOLKER, CHRISTOPHERChief Financial Officer500 events
CHRISTIANSON, MARKMarket Development Director281 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable NMTC filing ledger
Showing 1 to 8 of 8.
CHRISTIANSON, MARKMarket Development Director
AcquisitionOptions and derivatives
12500 sharesOption to Purchase Common Stock
Not reportedContext evidence
JOHNS, EMILY J.Chief Administrative Officer
AcquisitionOptions and derivatives
12500 sharesOption to Purchase Common Stock
Not reportedContext evidence
MERTENS, STEVEChief Technology Officer
AcquisitionOptions and derivatives
15000 sharesOption to Purchase Common Stock
Not reportedContext evidence
ROSA, DAVID ADirector, CEO & President
AcquisitionOptions and derivatives
68000 sharesOption to Purchase Common Stock
Not reportedContext evidence
VOLKER, CHRISTOPHERChief Financial Officer
AcquisitionOptions and derivatives
35000 sharesOption to Purchase Common Stock
Not reportedContext evidence
WAMBEKE, DAVID J.Chief Business Officer
AcquisitionOptions and derivatives
35000 sharesOption to Purchase Common Stock
Not reportedContext evidence
WAMBEKE, DAVID J.Chief Business Officer
AcquisitionCommon equity
33333 sharesCommon Stock
$67.0KDirectional evidence
CHRISTIANSON, MARKMarket Development Director
DisposalCommon equity
10000 sharesCommon Stock
$31.8KDirectional evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.